Biotech Consulting Owner Income: $180K Pay And 29-Month Breakeven
You’re planning a specialized biotech consulting firm, so owner income starts with billable work, expert labor, overhead, and cash timing This guide uses a five-year model with $180,000 modeled owner salary, $183,000 to $30 million revenue, and Month 29 breakeven It excludes personal taxes, guaranteed distributions, financing outcomes, and legal compensation advice
Owner income$183k–$30MNet margin83%–91%Revenue for target pay$183kBusiness difficultyHard
Want to test your owner pay target?
Owner income calculator
Estimate owner take-home and the target-pay gap from monthly revenue, gross margin, labor, overhead, reserves, and target pay.
!
Planning note: Research-based planning estimate only. It is not guaranteed salary, tax advice, or owner distribution advice.
Want the six main income drivers?
1
Billable Rate
$250-$360
Each hourly rate step lifts revenue fast, and most of that gain flows to owner income after fixed costs.
2
Utilization
20-45h
More billable hours per service pushes more work through the same team, so take-home rises without the same jump in overhead.
3
Client Mix
70%-80%
A heavier regulatory strategy mix keeps work in the highest-rate lane and supports stronger margins.
4
Delivery Leverage
17%-9%
Lower delivery cost load protects gross margin as the firm adds tools and outside help.
5
Overhead
$8.1K/mo
Fixed overhead sets the cash burn floor, so lean ops help breakeven come sooner.
6
Cash Policy
$422K
The minimum cash cushion decides how much growth the firm can fund before outside money is needed.
Want to see the forecast structure for Biotech Consulting?
Yes — the Biotech Consulting Financial Model Template shows the dashboard, income outputs, assumptions, scenario testing, revenue, gross margin, operating costs, staffing, cash flow, owner pay, and breakeven views. It’s a planning bridge, not the main answer.
Owner-income model highlights
$180,000 CEO salary
EBITDA turns positive
Month 29 breakeven
$422,000 minimum cash
47-month payback view
How much revenue is needed to pay a biotech consulting owner?
If you want Biotech Consulting to pay an owner $180,000 salary, the plan needs about $390,000 in revenue at a 71% contribution margin. If you also cover the modeled $352,200 of Year 1 payroll and fixed costs, the needed revenue rises to about $496,000; the Year 1 model revenue is only about $183,000, so profit does not fund that pay yet. That’s why treat owner pay as a planning output, not a promise; breakeven arrives in Month 29.
Owner pay math
$180,000 owner salary target
$97,200 fixed overhead
Need about $390,000 revenue
Uses 71% contribution margin
Year 1 reality
Modeled costs total $352,200
Need about $496,000 revenue
Year 1 revenue is about $183,000
Breakeven lands in Month 29
How much can a solo biotech consultant make?
A solo Biotech Consulting owner can bill $250–$300/hour in Year 1 and $290–$360/hour in Year 5, but take-home income is not the same as employee salary because owner profit depends on paid hours, collections, and overhead; see What Is The Most Critical Measure Of Success For Biotech Consulting? for the KPI angle. The provided model is not pure solo: it includes $255,000 Year 1 payroll and a $180,000 CEO salary, so use its rates and project math, not its payroll, to size solo income.
Solo rate math
Year 1 rate: $250–$300/hour
Year 5 rate: $290–$360/hour
Regulatory work: 20 × $250 = $5,000
Clinical work: 30 × $300 = $9,000
Owner reality
Market strategy: 25 × $275 = $6,875
Solo overhead can be lower
Founder time caps revenue
Model includes $180,000 CEO pay
Can a biotech consulting firm scale owner income?
Yes — Biotech Consulting can scale owner income, but only if delivery leverage stays high and utilization (billable time vs. available time) stays tight. Here’s the quick math: payroll rises from $255,000 in Year 1 to $1010 million in Year 5 as senior regulatory, clinical, market access, business development, and admin roles are added, while revenue grows from about $183,000 to $30 million. EBITDA moves from -$222,000 to $1419 million, but utilization gaps, client concentration, slow payments, quality control, and underpriced specialist work can still cap owner take-home.
Scale drivers
Revenue: $183,000 to $30 million
Payroll: $255,000 to $1010 million
EBITDA: -$222,000 to $1419 million
Owner income rises with leverage
Main risks
Utilization gaps cut margin fast
Client concentration raises volatility
Delayed payments strain cash flow
Low pricing hurts specialist work
Key Takeaways
Raise rates with scarce biotech expertise, not volume.
Utilization drives owner income when billable time stays high.
Retainers and larger projects smooth biotech revenue swings.
Fixed overhead and delayed cash can strain early reserves.
Compare biotech consulting owner income scenarios
Owner income scenarios
Owner income changes fast in the early years because payroll and overhead run ahead of revenue. Breakeven by Month 29 and Year 5 scale can lift take-home, but only if utilization stays high.
Low, base, and high cases show how profit and staffing change owner income.
Scenario
Low CaseLow Case
Base CaseBase Case
High CaseHigh Case
Launch model
The low case stays in launch mode, with Year 1 revenue near $183,000, a 71% contribution margin, and EBITDA at -$222,000.
The base case reaches Year 3 scale, with about $1.181 million revenue, 78% contribution margin, and $144,000 EBITDA around Month 29 breakeven.
The high case is a mature, leveraged model, with Year 5 revenue near $3.0 million, 84% contribution margin, and $1.419 million EBITDA.
Typical setup
The firm runs lean, with $352,200 payroll plus fixed overhead, a $180,000 modeled owner salary, and not enough profit to fully cover the founder's pay.
The firm has broadened delivery, with about $680,000 payroll, stronger mix across regulatory, clinical, and commercial work, and breakeven reached in Month 29.
The firm is scaled up, with about $1.01 million payroll, higher utilization, and enough profit for reserves, reinvestment, taxes, and distributions.
Cost drivers
Early client wins
high payroll load
fixed overhead
launch marketing
negative EBITDA
Higher utilization
stronger pricing
balanced service mix
Month 29 breakeven
$680k payroll
Year 5 scale
84% contribution margin
premium pricing
$1.01M payroll
$1.419M EBITDA
Owner income rangeBefore owner reserves
Below salary coverLow Case
$0 - $144,000Base Case
$1.0M - $1.4MHigh Case
Best fit
Use this to stress test the first operating year before the business reaches stable utilization.
Use this as the main planning case for a steady consulting build with normal ramp and controlled hiring.
Use this to test upside if the firm wins more work, keeps pricing firm, and hires without breaking margins.
!
Planning note: These ranges are researched planning assumptions, not guaranteed earnings, salary promises, tax advice, or distributions.
Biotech Consulting Core Six Income Drivers
Billable rate and premium expertise
Premium Billable Rates
Income rises when the firm charges for scarce judgment, not just hours. In Year 1, source hourly rates start at $250 for regulatory work, $300 for clinical strategy, and $275 for market strategy, so each engagement can produce more revenue without the same jump in overhead. That lifts gross profit and helps owner pay sooner.
By Year 5, rates reach $290, $360, and $315. The risk is simple: if pricing stays below the value of biotech strategy, regulatory planning, clinical trial design, or technical due diligence, the owner does more expert work for the same cash. One clean price change can matter more than adding more lead volume.
Price for Scarcity
Track realized hourly rate by service line, not just booked hours. If clinical work earns $300 to $360 per hour and regulatory work earns $250 to $290, the mix will shape revenue quality and cash flow. Here’s the quick math: higher rates raise revenue per engagement, while fixed costs stay flat if delivery stays lean.
Track rate by service
Review discount frequency monthly
Quote by scope, not vibes
Protect specialty-only work
What this estimate hides: low pricing can also pull in more scope creep, longer payment cycles, and weaker margins. If the work needs senior scientific or regulatory judgment, price it that way and document the scope tightly so the owner’s take-home income grows with expertise, not just with hours logged.
Utilization and billable capacity
Utilization and Billable Capacity
Utilization is the share of available work time that turns into paid client work. In biotech consulting, service blocks are typically 20-25 hours for regulatory strategy, 30-45 hours for clinical trial design, and 25-35 hours for market commercial strategy, so proposals, calls, research, conferences, admin, and hiring directly cut billable time.
That hits revenue, cash flow, and the owner’s draw fast. If the founder also sells, manages, and delivers the work, utilization becomes the main ceiling on income; once delivery time is full, growth has to come from higher rates, more support, or a tighter client mix.
Measure and Protect Billable Time
Track billed hours, available hours, and non-billable time by service line every month. The key formula is billed hours ÷ available hours. Split out proposals, discovery calls, research, conferences, admin, and hiring so you can see which tasks are eating paid capacity before they hit profit.
Protect owner income by pushing low-value admin off the founder’s desk and keeping founder time on the highest-price work. If one client or one project uses most capacity, revenue gets lumpy and take-home pay is exposed when a project ends or a sales cycle runs long.
Operating overhead and credibility costs
Trust-Building Overhead
For a biotech consulting firm, this driver is the tradeoff between looking credible and staying cash-light. Fixed costs total $8,100 per month for rent, insurance, legal, software, secure cloud storage, utilities, accounting, and supplies, so every added dollar must be covered by billable work before owner pay can rise.
The marketing budget moves from $25,000 to $100,000, while CAC drops from $5,000 to $3,500. That is a 30% CAC improvement, but it still only helps if the new leads turn into real engagements. If spend rises before revenue quality is proven, cash flow tightens fast.
Stage-Gate the Spend
Track fixed overhead, CAC, signed client revenue, and cash runway each month. Here’s the quick math: a 4x jump in marketing spend only makes sense if it brings steadier lead flow and enough closed work to cover the $8,100 base cost plus delivery time. Otherwise, the founder is buying visibility, not profit.
Cap hires to booked revenue.
Review CAC by channel monthly.
Require signed work before adding tools.
Delay fixed spend until close rates hold.
What this estimate hides is conversion quality. A lower CAC is useful only if clients stay long enough to cover setup, compliance, and delivery effort. In this model, the safest path is to spend on trust signals that win better leads, then keep overhead lean until recurring revenue is stable.
Reserves, reinvestment, and owner draw policy
Owner draw and reserve discipline
Owner draw is extra cash you take after the business covers payroll, taxes, and reserves. It is not the same as taxable income or a guaranteed salary. This model includes a $180,000 CEO salary, but EBITDA is still -$222,000 in Year 1 and -$125,000 in Year 2, so owner pay has to stay tight until cash turns positive.
The cash gap is real: minimum cash need is $422,000, breakeven is Month 29, and payback is 47 months. That means take-home income depends more on collected cash than booked revenue. Delayed client payments, lumpy projects, hiring, marketing, and research tool renewals can cut draw capacity fast.
Keep draw tied to cash in hand
Set owner draw only after payroll, taxes, and the $422,000 cash need are covered. In a negative EBITDA build, don’t fund draw from projected revenue. Use cash collected, not invoices sent, as the trigger.
Track cash collected, days sales outstanding, and the reserve balance each month. If a project slips or a renewal lands early, pause draw first. That protects the business through the Month 29 breakeven stretch and keeps owner income safer later.
Pay salary before any draw.
Hold reserve above cash need.
Link draw to collections.
Review renewals before payment dates.
Client mix and engagement structure
Client Mix and Engagement Structure
More retainers and larger strategy jobs make owner income steadier. In this model, regulatory strategy runs at 70% to 80%, clinical trial design at 40% to 60%, and market commercial strategy at 30% to 50%. Those percentages can overlap because one client may buy more than one service. The result is smoother revenue, better scope control, and less pressure on monthly owner pay when short projects end.
Track mix, not just sales
Watch how much revenue comes from short projects versus advisory retainers and larger engagements. Here’s the key risk: a few large biotech clients can drive too much of the pipeline, so one delay can hit cash flow fast. Use clear scopes, milestone billing, and separate service lines so each account shows what it buys, what it renews, and what it should pay for next.
Track retainer share by client
Count services per account
Flag top-client concentration
Review scope changes fast
Delivery leverage through specialists
Specialist delivery leverage
Biotech consulting can grow beyond the founder’s hours when subcontracted regulatory, clinical, market research, or scientific experts help deliver projects. The key tradeoff is margin: external expert consultation is modeled at 4% of revenue in Year 1, easing to 2% by Year 5, so each $1 of sales must cover that cost before owner pay improves.
This driver raises income when senior consultants take on delivery and the founder stops being the only bottleneck. Here’s the quick math: if expert fees are not built into project pricing, gross margin shrinks and cash gets tighter. The main risks are lower gross margin, a weak review process, and uneven client quality.
Price the expert layer into every project
Track project revenue, subcontractor cost, and senior consultant utilization on each job. The goal is simple: keep expert help tied to billable work, not overhead. If a project needs regulatory, clinical, or scientific review, the fee should carry that cost so owner draw comes from margin, not hope.
